2-Methyl-DMT
| Clinical data | |
|---|---|
| Other names | 2-Me-DMT; 2-Methyl-N,N-dimethyltryptamine; 2,N,N-Trimethyltryptamine; 2,N,N-TMT; 2-TMT; Desmethoxy-Indapex; 3-[2-(Dimethylamino)ethyl]-2-methylindole; |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Duration of action | 4–6 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C13H18N2 |
| Molar mass | 202.301 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
2-Methyl-DMT, or 2-Me-DMT, also known as 2-methyl-N,N-dimethyltryptamine or as 2,N,N-trimethyltryptamine (2,N,N-TMT or 2-TMT), is a psychoactive drug of the tryptamine family related to the psychedelic drug dimethyltryptamine (DMT). It is not a conventional psychedelic, but instead produces tactile enhancement and auditory distortion. The drug was described by Alexander Shulgin and reported in his book TiHKAL (Tryptamines I Have Known and Loved).
Category:
- Drugs not assigned an ATC code